Heartflow (HTFL) vs Envista (NVST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Heartflow (HTFL) has outperformed Envista (NVST) over the past year, gaining 51.3% versus a gain of 15.2%. Heartflow is the larger company by market cap ($4.10 billion vs $3.67 billion), about 1.1 times the size. On valuation, Envista trades at a lower trailing P/E (6.0x vs 69.7x for Heartflow).
Envista converts more of its revenue into profit, with a net margin of 1.7% versus -66.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HTFL | NVST |
|---|---|---|
| Share price | $46.69 | $22.91 |
| Market cap | $4.10B | $3.67B |
| 1-day change | +4.62% | -1.55% |
| YTD return | +60.17% | +5.53% |
| 1-year return | +51.35% | +15.18% |
| 5-year return | — | -42.84% |
| P/E ratio (TTM) | 69.69 | 5.95 |
| Forward P/E | — | 13.68 |
| EPS (TTM) | $0.67 | $3.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $176.03M | $2.72B |
| Revenue growth (YoY) | +39.92% | +8.32% |
| Net income (latest FY) | $-116.79M | $47.00M |
| Gross margin | 76.80% | 54.67% |
| Operating margin | -36.39% | 7.95% |
| Net margin | -66.35% | 1.73% |
| 52-week high | $60.66 | $30.42 |
| 52-week low | $20.13 | $19.67 |
| Distance from 52-week high | -23.02% | -24.69% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +39.22% | +26.23% |
| Average volume | 1.84M | 2.87M |
| Shares outstanding | 87.89M | 160.34M |
| Employees | 843 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HTFL has outperformed NVST by 36.2 percentage points over the past year.
- Heartflow trades at a higher earnings multiple (69.7x vs 6.0x trailing P/E).
- Envista is more profitable, keeping 1.7 cents of every revenue dollar as net income versus -66.3 cents for Heartflow.
- Heartflow grew revenue faster in its latest fiscal year (+39.92% vs +8.32%).
About Heartflow
HTFL stock →HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries.
Health Care · Medical/Dental Instruments · 843 employees
About Envista
NVST stock →Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
Health Care · Medical/Dental Instruments · 12,000 employees
HTFL vs NVST FAQ
Which is bigger, Heartflow or Envista?
Heartflow (HTFL) is larger, with a market capitalization of $4.10B compared with $3.67B for Envista (NVST).
Which stock has performed better over the past year, HTFL or NVST?
HTFL returned +51.35% over the past 12 months, compared with +15.18% for NVST (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HTFL or NVST?
NVST has the lower trailing P/E at 6.0, versus 69.7 for HTFL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Heartflow and Envista in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.